A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection
Status:
Completed
Trial end date:
2017-10-16
Target enrollment:
Participant gender:
Summary
This randomized, multicenter, partially double-blind, placebo-controlled study is designed to
evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral effects
of treatment with RO6864018 in virologically suppressed participants with chronic HBV
infection.